Recombinant human alpha-glucosidase from rabbit milk in Pompe patients

Lancet. 2000 Jul 29;356(9227):397-8. doi: 10.1016/s0140-6736(00)02533-2.

Abstract

Pompe's disease is a fatal muscular disorder caused by lysosomal alpha-glucosidase deficiency. In an open-label study, four babies with characteristic cardiomyopathy were treated with recombinant human alpha-glucosidase (rhGAA) from rabbit milk at starting doses of 15 mg/kg or 20 mg/kg, and later 40 mg/kg. The enzyme was generally well tolerated. Activity of alpha-glucosidase normalised in muscle. Tissue morphology and motor and cardiac function improved. The left-ventricular-mass index decreased significantly. We recommend early treatment. Long-term effects are being studied.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Genetically Modified
  • Cardiomyopathy, Hypertrophic / complications
  • Cardiomyopathy, Hypertrophic / drug therapy
  • Glycogen Storage Disease Type II / complications
  • Glycogen Storage Disease Type II / drug therapy*
  • Humans
  • Milk / chemistry
  • Rabbits
  • Recombinant Proteins / isolation & purification
  • Recombinant Proteins / therapeutic use
  • alpha-Glucosidases / isolation & purification
  • alpha-Glucosidases / therapeutic use*

Substances

  • Recombinant Proteins
  • alpha-Glucosidases